-+ 0.00%
-+ 0.00%
-+ 0.00%
Tianjin Pharmaceutical announced that the company recently received the DMF First Medication Letter issued by the US FDA. The drug involved is betamethasone. The company submitted a betamethasone API application to the FDA in September 2019. Up to now, the project has invested about 3 million yuan in R&D. The letter indicates that the FDA has completed a scientific review of the DMF file for the company's betamethasone API, which can meet the ANDA reporting requirements of related formulation customers.
Share
Listen to the news
Tianjin Pharmaceutical announced that the company recently received the DMF First Medication Letter issued by the US FDA. The drug involved is betamethasone. The company submitted a betamethasone API application to the FDA in September 2019. Up to now, the project has invested about 3 million yuan in R&D. The letter indicates that the FDA has completed a scientific review of the DMF file for the company's betamethasone API, which can meet the ANDA reporting requirements of related formulation customers.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending